查看文章

Tumor hypoxia is associated with poor response to therapy. We have investigated whether pretreatment tumor hypoxia assessed by positron emission tomography (PET) with Cu-60 diacetyl-bis(N⁴-methylthiosemicarbazone) (⁶⁰Cu-ATSM) predicts responsiveness to subsequent therapy in cervical cancer.

Fourteen patients with biopsy-proved cervical cancer were studied by PET with ⁶⁰Cu-ATSM before initiation of radiotherapy and chemotherapy. ⁶⁰Cu-ATSM uptake was evaluated semiquantitatively by determining the tumor-to-muscle activity ratio (T/M) and peak slope index of tumor tracer uptake. All patients also underwent clinical PET with F-18 fluorodeoxyglucose (FDG) before institution of therapy. The PET results were correlated with follow-up evaluation (14–24 months).

Tumor uptake of ⁶⁰Cu-ATSM was inversely related to progression-free survival and …